Form 4: CRISPR CEO Sells Shares Under 10b5-1 Plan

CRISPR Therapeutics CEO Samarth Kulkarni sold a total of 90,000 common shares in pre-planned transactions in January 2026.

Summary

• Samarth Kulkarni, CEO and Director of CRISPR Therapeutics AG (CRSP), reported the sale of 90,000 common shares.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 27, 2025.
• On January 20, 2026, 21,433 shares were sold at a weighted average price of $51.61, ranging from $51.00 to $51.99.
• Also on January 20, 2026, an additional 8,567 shares were sold at a weighted average price of $52.10, ranging from $52.00 to $52.45.
• On January 22, 2026, 60,000 shares were sold at a weighted average price of $60.23, ranging from $60.00 to $60.61.
• Following these transactions, Kulkarni directly beneficially owns 134,201 common shares.
• Kulkarni also indirectly beneficially owns 85,622 common shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: The sentiment is neutral. Insider sales under a Rule 10b5-1 plan are typically for personal financial planning and do not necessarily reflect management's immediate view on the company's prospects. The increasing prices at which shares were sold could be seen as a positive trend, balancing any potential negative perception of insider selling.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions for personal financial planning rather than a reaction to immediate company performance, which is a positive for corporate governance.
• The sales occurred at increasing prices, with the final block sold at an average of $60.23, which could be seen as a positive trend in the stock's valuation during the transaction period.

Negatives

• Insider selling, even if pre-planned, reduces the CEO's direct ownership stake in the company, which some investors might view as a slight reduction in alignment of interests with shareholders.

Future Outlook

NA

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common occurrence across all industries. For a biotechnology company like CRISPR Therapeutics, such pre-planned sales are generally viewed as routine personal financial management by executives and are less likely to signal specific operational or strategic shifts compared to unscheduled sales.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe a reduction in the CEO's direct ownership, but the pre-planned nature of the sales under a 10b5-1 plan generally mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The filing reports pre-scheduled insider sales by the CEO under a Rule 10b5-1 trading plan. Such sales are typically for personal financial planning and do not necessarily reflect a change in management's outlook on the company's future. While insider selling can sometimes be a negative signal, the pre-planned nature and the increasing prices at which shares were sold suggest a neutral to slightly positive interpretation regarding the stock's immediate trajectory. Without additional financial or operational information, a 'hold' recommendation is appropriate.

Keywords

CRISPR Therapeutics, CRSP, Insider Trading, Form 4, Stock Sale, Samarth Kulkarni, CEO, 10b5-1 Plan, Biotechnology, Gene Editing